Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index; 15 of the 25 sources its claims cite were checked for support.

The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling

Open access
Storer Samaniego, Cheryl, Suh, Ji Ho, Chattopadhyay, Arundhati, Olivares, Karen, Guy, Naihsuan, Sivils, Jeffrey C., Dey, Prasenjit, Yumoto, Fumiaki, Fletterick, Robert J., Strom, Anders M., Gustafsson, Jan-Åke, Webb, Paul, Cox, Marc B. · 2015 · PLOS One

Abstract

FKBP52 and β-catenin have emerged in recent years as attractive targets for prostate cancer treatment. β-catenin interacts directly with the androgen receptor (AR) and has been characterized as a co-activator of AR-mediated transcription. FKBP52 is a positive regulator of AR in cellular and whole animal models and is required for the development of androgen-dependent tissues. We previously characterized an AR inhibitor termed MJC13 that putatively targets the AR BF3 surface to specifically inhibit FKBP52-regulated AR signaling. Predictive modeling suggests that β-catenin interacts with the AR hormone binding domain on a surface that overlaps with BF3. Here we demonstrate that FKBP52 and β-catenin interact directly in vitro and act in concert to promote a synergistic up-regulation of both hormone-independent and -dependent AR signaling. Our data demonstrate that FKBP52 promotes β-catenin interaction with AR and is required for β-catenin co-activation of AR activity in prostate cancer cells. MJC13 effectively blocks β-catenin interaction with the AR LBD and the synergistic up-regulation of AR by FKBP52 and β-catenin. Our data suggest that co-regulation of AR by FKBP52 and β-catenin does not require FKBP52 PPIase catalytic activity, nor FKBP52 binding to Hsp90. However, the FKBP52 proline-rich loop that overhangs the PPIase pocket is critical for synergy.

Overview

CoChat Summary

## TL;DR

FKBP52 and β-catenin directly cooperate to enhance androgen receptor (AR) signaling, and FKBP52 is required for β-catenin’s co-activation of AR in the systems tested. The AR inhibitor MJC13 blocked the β-catenin–AR interaction and abolished the synergistic AR activation driven by FKBP52 plus β-catenin.

## Key findings

  • In a cell-free GST pull-down assay, recombinant FKBP52 directly co-precipitated with GST-tagged β-catenin, showing a direct FKBP52–β-catenin interaction in vitro.
  • In 52KO mouse embryonic fibroblasts, co-expression of FKBP52 with β-catenin or β-catenin S33A produced synergistic AR reporter activation: 17-fold and 25-fold enhancement of hormone-dependent AR activity, respectively, and 10-fold enhancement of hormone-independent activity.
  • In HeLa cells, co-expression of FKBP52 and β-catenin S33Y increased Gal4-AR LBD activity 9-fold; FKBP52 knockdown reduced β-catenin-driven AR LBD activity by 2-fold and 4-fold in the conditions described.
  • In 22Rv1 prostate cancer cells, β-catenin S33A potentiated AR-mediated luciferase expression up to 3-fold in wild-type cells, but this effect was lost or not statistically significant after FKBP52 knockdown; MJC13 completely inhibited both hormone-independent and hormone-dependent AR activity mediated by FKBP52 and β-catenin at low micromolar concentrations.

## Methods

  • The study used multiple cell systems: 52KO MEF, HeLa, 293T, LNCaP, and 22Rv1 cells, plus recombinant proteins for in vitro binding assays.
  • Main assays included GST pull-down, co-immunoprecipitation, mammalian two-hybrid, and luciferase reporter assays to test FKBP52–β-catenin interaction and effects on AR signaling.
  • Functional tests included FKBP52 overexpression, siRNA/shRNA knockdown, AR and β-catenin mutant constructs, DHT stimulation, and treatment with MJC13.

## Limitations

  • The paper states that the hormone-independent effects were inconsistent between assays, so no firm conclusions could be drawn about that component.
  • The authors note that stable FKBP52 knockdown could not be achieved in LNCaP and PC3 cells, limiting prostate-cancer-cell testing to 22Rv1 cells; this is stated in the paper.
  • Evident from the text: several conclusions rely on overexpression and reporter assays, which may not fully capture endogenous AR signaling context.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0134015

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 The Predicted β-Catenin Binding Site on AR is Near the Putative FKBP52 Regulatory Surface. (A) Structure of the complex of nuclear receptor LRH-1 with β-catenin, PDB ID 3tx7. β-catenin is shown with a semi-transparent surface in yellow revealing its secondary structure elements as ribbons. LRH-1 is shown with blue ribbons for its secondary structure. The interfacial surface of these two molecules is shown in teal on the β-catenin surface. (B) Flufenamic acid from PDB ID 2PIT is shown in purple spheres as it binds to the androgen receptor shown with its secondary structure as teal colored ribbons. The Cα coordinates of androgen receptor in 2PIT were superimposed with the Cα coordinates of LRH-1 in 3TX7.
Fig 1 The Predicted β-Catenin Binding Site on AR is Near the Putative FKBP52 Regulatory Surface. (A) Structure of the complex of nuclear receptor LRH-1 with β-catenin, PDB ID 3tx7. β-catenin is shown with a semi-transparent surface in yellow revealing its secondary structure elements as ribbons. LRH-1 is shown with blue ribbons for its secondary structure. The interfacial surface of these two molecules is shown in teal on the β-catenin surface. (B) Flufenamic acid from PDB ID 2PIT is shown in purple spheres as it binds to the androgen receptor shown with its secondary structure as teal colored ribbons. The Cα coordinates of androgen receptor in 2PIT were superimposed with the Cα coordinates of LRH-1 in 3TX7.CC BY · PubMed Central
Fig 2 FKBP52 Directly Interacts with β-Catenin to Promote Interaction with AR. (A) In vitro GST-pull down assays were performed with purified, recombinant FKBP52 alone, GST-Tagged β-catenin alone, and both recombinant proteins together. Proteins were visualized on Western Blots with primary antibodies specific to human FKBP52 and β-catenin. (B) A mammalian two-hybrid assay assessing the DHT-dependent activity of a Gal4-mediated luciferase reporter in the presence or absence of a Gal4-AR LBD fusion, Vp16-β-catenin and/or FKBP52 demonstrating that FKBP52 potentiates VP-16-β-catenin/AR interaction in 293 cells. Asterisks (***) denote that hormone-dependent reporter expression in the presence of FKBP52, Vp16-β-catenin, and Gal4-AR LBD was significantly enhanced (p values ranging from < 0.01 to < 0.001) as compared to all other conditions. Hormone-dependent reporter expression in the presence of Gal4-AR LBD with FKBP52 or β-catenin alone did not significantly differ (p > 0.05) from the control with Gal4-AR LBD alone. C. A co-immunoprecipitation to detect β-catenin interaction with FKBP52 and AR with and without DHT and FKBP52 siRNA in LNCaP cell lysates. β-catenin was immunoprecipitated and blots probed for AR, FKBP52 or β-catenin. Inputs are shown at bottom. Note that FKBP52 knockdown results in reduced AR/β-catenin interaction despite similar levels of input.
Fig 2 FKBP52 Directly Interacts with β-Catenin to Promote Interaction with AR. (A) In vitro GST-pull down assays were performed with purified, recombinant FKBP52 alone, GST-Tagged β-catenin alone, and both recombinant proteins together. Proteins were visualized on Western Blots with primary antibodies specific to human FKBP52 and β-catenin. (B) A mammalian two-hybrid assay assessing the DHT-dependent activity of a Gal4-mediated luciferase reporter in the presence or absence of a Gal4-AR LBD fusion, Vp16-β-catenin and/or FKBP52 demonstrating that FKBP52 potentiates VP-16-β-catenin/AR interaction in 293 cells. Asterisks (***) denote that hormone-dependent reporter expression in the presence of FKBP52, Vp16-β-catenin, and Gal4-AR LBD was significantly enhanced (p values ranging from < 0.01 to < 0.001) as compared to all other conditions. Hormone-dependent reporter expression in the presence of Gal4-AR LBD with FKBP52 or β-catenin alone did not significantly differ (p > 0.05) from the control with Gal4-AR LBD alone. C. A co-immunoprecipitation to detect β-catenin interaction with FKBP52 and AR with and without DHT and FKBP52 siRNA in LNCaP cell lysates. β-catenin was immunoprecipitated and blots probed for AR, FKBP52 or β-catenin. Inputs are shown at bottom. Note that FKBP52 knockdown results in reduced AR/β-catenin interaction despite similar levels of input.CC BY · PubMed Central
Fig 3 FKBP52 is Specifically Required for β-Catenin Potentiation of AR Activity. (A) AR-mediated luciferase assay in 52KO MEFs in the presence of the indicated transiently transfected expression plasmids with (Black bars) or without (grey bars) dihydrotestosterone (DHT). The asterisks denote a statistically significant difference (***p < 0.001; ****p < 0.0001) as compared to vector alone for each hormone condition. Hormone-dependent receptor activity in the presence FKBP52 and β-catenin also significantly differed as compared to activity in the presence of FKBP52 and β-catenin (S33A) (p < 0.001). The activity in the presence of FKBP52 and wild type or mutant β-catenin was also significantly higher in the presence of hormone than in the absence (p < 0.0001). All other conditions did not significantly differ from the vector alone control, or from each other for each hormone condition. (B) DHT-dependent activity of a Gal4-mediated luciferase reporter in the presence or absence of a Gal4-AR LBD fusion, β-catenin (S33Y) and/or FKBP52 was assessed in HeLa cells. The asterisks denote a statistically significant difference (**p < 0.01; ***p < 0.001) as compared to Gal4-AR LBD alone in the presence of DHT. Hormone-dependent Gal4-AR LBD activity in the presence of both β-catenin (S33Y) and FKBP52 was also significantly (p < 0.001) potentiated as compared to activity in the presence of either β-catenin (S33Y) or FKBP52 alone. (C) The same as in (B), except that transient, siRNA-mediated FKBP52 knockdown was assessed instead of overexpression. The asterisks denote a statistically significant difference (***p < 0.001) as compared to Gal4-AR LBD alone in the presence of DHT. Hormone-dependent Gal4-AR LBD activity in the presence of both β-catenin (S33Y) and Si-FKBP52 was also significantly (p < 0.001) reduced as comparecd to activity in the presence of β-catenin (S33Y) alone. (D) As a control for AR specificity, β-catenin (S33Y) potentiation of TCF4-mediated luciferase activity in HeLa cells was assessed in the presence or absence of FKBP52 overexpression. The asterisks denote a statistically significant (***p < 0.001) potentiation of TCF4-mediated luciferase activity as compared to all other conditions in the absence of β-catenin (S33Y). TCF4-mediated luciferase activity in the presence of β-catenin (S33Y) was not statistically (p > 0.05) different in the presence or absence of FKBP52.
Fig 3 FKBP52 is Specifically Required for β-Catenin Potentiation of AR Activity. (A) AR-mediated luciferase assay in 52KO MEFs in the presence of the indicated transiently transfected expression plasmids with (Black bars) or without (grey bars) dihydrotestosterone (DHT). The asterisks denote a statistically significant difference (***p < 0.001; ****p < 0.0001) as compared to vector alone for each hormone condition. Hormone-dependent receptor activity in the presence FKBP52 and β-catenin also significantly differed as compared to activity in the presence of FKBP52 and β-catenin (S33A) (p < 0.001). The activity in the presence of FKBP52 and wild type or mutant β-catenin was also significantly higher in the presence of hormone than in the absence (p < 0.0001). All other conditions did not significantly differ from the vector alone control, or from each other for each hormone condition. (B) DHT-dependent activity of a Gal4-mediated luciferase reporter in the presence or absence of a Gal4-AR LBD fusion, β-catenin (S33Y) and/or FKBP52 was assessed in HeLa cells. The asterisks denote a statistically significant difference (**p < 0.01; ***p < 0.001) as compared to Gal4-AR LBD alone in the presence of DHT. Hormone-dependent Gal4-AR LBD activity in the presence of both β-catenin (S33Y) and FKBP52 was also significantly (p < 0.001) potentiated as compared to activity in the presence of either β-catenin (S33Y) or FKBP52 alone. (C) The same as in (B), except that transient, siRNA-mediated FKBP52 knockdown was assessed instead of overexpression. The asterisks denote a statistically significant difference (***p < 0.001) as compared to Gal4-AR LBD alone in the presence of DHT. Hormone-dependent Gal4-AR LBD activity in the presence of both β-catenin (S33Y) and Si-FKBP52 was also significantly (p < 0.001) reduced as comparecd to activity in the presence of β-catenin (S33Y) alone. (D) As a control for AR specificity, β-catenin (S33Y) potentiation of TCF4-mediated luciferase activity in HeLa cells was assessed in the presence or absence of FKBP52 overexpression. The asterisks denote a statistically significant (***p < 0.001) potentiation of TCF4-mediated luciferase activity as compared to all other conditions in the absence of β-catenin (S33Y). TCF4-mediated luciferase activity in the presence of β-catenin (S33Y) was not statistically (p > 0.05) different in the presence or absence of FKBP52.CC BY · PubMed Central
Fig 4 FKBP52 is Required for β-Catenin Potentiation of AR in 22Rv1 Prostate Cancer Cells. (A) AR-mediated probasin-luciferase activity was assessed at a range of hormone concentrations in 22Rv1 prostate cancer cells stably transfected with a 19 base pair shRNA directed against FKBP52 (52KD) or wild type 22Rv1 cells. Significant differences at each hormone concentration are indicated (***p < 0.001). The upper panels show Western blots for AR (both the full length and truncated ARs are shown), FKBP52, and GAPDH as a loading control from 52KD and wild type 22Rv1 cell lysates. (B) A luciferase reporter assay using the AR-inducible probasin-luciferase reporter plasmid in wild type and 52KD 22Rv1 cells with and without overexpression of the indicated proteins in the presence or absence of 175 pM dihydrotestosterone (DHT). Reporter expression in the presence of β-catenin (S33A) and DHT is significantly different from all other conditions (p < 0.001). Wild type cells with empty vector alone in the presence of DHT also significantly differed from all other conditions with p values ranging from < 0.05 to < 0.001. No conditions in the presence of FKBP52 knockdown significantly differed from each other in pairwise comparisons (p>0.05).
Fig 4 FKBP52 is Required for β-Catenin Potentiation of AR in 22Rv1 Prostate Cancer Cells. (A) AR-mediated probasin-luciferase activity was assessed at a range of hormone concentrations in 22Rv1 prostate cancer cells stably transfected with a 19 base pair shRNA directed against FKBP52 (52KD) or wild type 22Rv1 cells. Significant differences at each hormone concentration are indicated (***p < 0.001). The upper panels show Western blots for AR (both the full length and truncated ARs are shown), FKBP52, and GAPDH as a loading control from 52KD and wild type 22Rv1 cell lysates. (B) A luciferase reporter assay using the AR-inducible probasin-luciferase reporter plasmid in wild type and 52KD 22Rv1 cells with and without overexpression of the indicated proteins in the presence or absence of 175 pM dihydrotestosterone (DHT). Reporter expression in the presence of β-catenin (S33A) and DHT is significantly different from all other conditions (p < 0.001). Wild type cells with empty vector alone in the presence of DHT also significantly differed from all other conditions with p values ranging from < 0.05 to < 0.001. No conditions in the presence of FKBP52 knockdown significantly differed from each other in pairwise comparisons (p>0.05).CC BY · PubMed Central
Fig 5 The FKBP52 Domain Requirements for FKBP52/β-Catenin Co-Regulation of AR Activity. (A-C) Wild type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active β-galactosidase reporter plasmid were cotransfected simultaneously with each of the plasmids indicated for the different treatment groups in 52KO MEF cells. Cells were induced with 10 pM DHT or ethanol. Following cell lysis, AR expression was tested through a luciferase assay, followed by normalization to β-galactosidase activity. In all graphs, statistically significant differences as compared to the vector alone control for each hormone condition are denoted by asterisks (*p < 0.05; ***p < 0.001). (A) The assay was performed in the presence or absence of FKBP52, β-catenin (S33A), and the PPIase-deficient FKBP52 mutant FKBP52 (F130Y). The PPIase-deficient FKBP52 mutant retains the ability to synergize with β-catenin (S33A) indicating that PPIase enzymatic activity is not critical for synergy. (B) The assay was performed in the presence or absence of β-catenin (S33A), FKBP52, and the Hsp90 binding-deficient mutant FKBP52 (K354A). FKBP52 binding to Hsp90 is not required for the synergistic upregulation of AR activity by FKBP52 and β-catenin. C. The assay was performed in the presence or absence of β-catenin (S33A), FKBP52, FKBP51, and the FKBP51 (A116V/L119P) mutant. The FKBP51 gain of function mutant exhibits substantial synergism with β-catenin indicating that the FK1 domain and the proline-rich loop are important for synergy.
Fig 5 The FKBP52 Domain Requirements for FKBP52/β-Catenin Co-Regulation of AR Activity. (A-C) Wild type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active β-galactosidase reporter plasmid were cotransfected simultaneously with each of the plasmids indicated for the different treatment groups in 52KO MEF cells. Cells were induced with 10 pM DHT or ethanol. Following cell lysis, AR expression was tested through a luciferase assay, followed by normalization to β-galactosidase activity. In all graphs, statistically significant differences as compared to the vector alone control for each hormone condition are denoted by asterisks (*p < 0.05; ***p < 0.001). (A) The assay was performed in the presence or absence of FKBP52, β-catenin (S33A), and the PPIase-deficient FKBP52 mutant FKBP52 (F130Y). The PPIase-deficient FKBP52 mutant retains the ability to synergize with β-catenin (S33A) indicating that PPIase enzymatic activity is not critical for synergy. (B) The assay was performed in the presence or absence of β-catenin (S33A), FKBP52, and the Hsp90 binding-deficient mutant FKBP52 (K354A). FKBP52 binding to Hsp90 is not required for the synergistic upregulation of AR activity by FKBP52 and β-catenin. C. The assay was performed in the presence or absence of β-catenin (S33A), FKBP52, FKBP51, and the FKBP51 (A116V/L119P) mutant. The FKBP51 gain of function mutant exhibits substantial synergism with β-catenin indicating that the FK1 domain and the proline-rich loop are important for synergy.CC BY · PubMed Central
Fig 6 The FKBP52-Specific AR Inhibitor MJC13 Blocks β-Catenin Interaction with AR and Potentiation of AR Activity. (A) A co-IP assay to detect β-catenin interaction with Gal4-AR LBD in 293 cells. Proteins were immunoprecipitated with an anti-Gal4 antibody in lysates from 293 cells treated with or without indicated concentrations of DHT and MJC13. AR LBD was precipitated and blots probed for AR or β-catenin +/- DHT and MJC13. Inputs are shown at bottom. (B) A mammalian two-hybrid assay assessing the DHT-dependent activity of a Gal4-mediated luciferase reporter in the presence of a Gal4-AR LBD fusion with and without Vp16-β-catenin and 30 μM MJC13. MJC13 significantly (***p < 0.001) inhibits hormone-dependent Vp16 β-catenin/Gal4-AR LBD interaction in 293. Both conditions in the presence of Vp16 β-catenin were significantly (p < 0.001) enhanced as compared to hormone-dependent activity in the presence of Gal$-AR LBD alone. (C) 52KO MEFs were co-transfected with FKBP52, β-catenin (S33A), wild type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active β-galactosidase reporter plasmid. After a 1 hour soak with a range of concentrations of MJC13, cells were induced with 10 pM DHT or ethanol for 16 hours. Following cell lysis, AR expression was assessed by luciferase assay. The data represent the average reporter expression (luciferase activity/β-galactosidase activity +/- standard deviation) of four replicates. MJC13 significantly (p < 0.001) inhibited hormone-dependent activity at all concentrations at or above 1 μM. MJC13 significantly inhibited hormone-independent activity at the 2.5 μM (p < 0.05), 5 μM (p < 0.01), and 10 μM (p < 0.05) concentrations.
Fig 6 The FKBP52-Specific AR Inhibitor MJC13 Blocks β-Catenin Interaction with AR and Potentiation of AR Activity. (A) A co-IP assay to detect β-catenin interaction with Gal4-AR LBD in 293 cells. Proteins were immunoprecipitated with an anti-Gal4 antibody in lysates from 293 cells treated with or without indicated concentrations of DHT and MJC13. AR LBD was precipitated and blots probed for AR or β-catenin +/- DHT and MJC13. Inputs are shown at bottom. (B) A mammalian two-hybrid assay assessing the DHT-dependent activity of a Gal4-mediated luciferase reporter in the presence of a Gal4-AR LBD fusion with and without Vp16-β-catenin and 30 μM MJC13. MJC13 significantly (***p < 0.001) inhibits hormone-dependent Vp16 β-catenin/Gal4-AR LBD interaction in 293. Both conditions in the presence of Vp16 β-catenin were significantly (p < 0.001) enhanced as compared to hormone-dependent activity in the presence of Gal$-AR LBD alone. (C) 52KO MEFs were co-transfected with FKBP52, β-catenin (S33A), wild type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active β-galactosidase reporter plasmid. After a 1 hour soak with a range of concentrations of MJC13, cells were induced with 10 pM DHT or ethanol for 16 hours. Following cell lysis, AR expression was assessed by luciferase assay. The data represent the average reporter expression (luciferase activity/β-galactosidase activity +/- standard deviation) of four replicates. MJC13 significantly (p < 0.001) inhibited hormone-dependent activity at all concentrations at or above 1 μM. MJC13 significantly inhibited hormone-independent activity at the 2.5 μM (p < 0.05), 5 μM (p < 0.01), and 10 μM (p < 0.05) concentrations.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 9 Not checked · 86 Own results and interpretations

74 more claims · 1 with their cited sources checked

Create a free account to see all 109 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Citations

Cites

Show all 34 references

Cited by

See all 13

Metadata

Authors
Storer Samaniego, C., Suh, J. H., Chattopadhyay, A., Olivares, K., Guy, N., Sivils, J. C., Dey, P., Yumoto, F., Fletterick, R. J., Strom, A. M., Gustafsson, J.-Å., Webb, P., & Cox, M. B.
Affiliations
  • Houston Methodist (US)
  • The University of Texas at El Paso (US)
  • University of Houston (US)
  • University of California, San Francisco (US)
Corresponding author
Cox, Marc B.
Venue
PLOS One
Published
2015-07-24
Volume
10
Issue
7
Pages
e0134015
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2141176467
Cited by
13
References
34
Citations by year
2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2015: 1
FWCI
1.84
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kettering University Digital Commons (Kettering University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Prevention and Research Institute of Texas (RP110444-C2, RP110444-P2, RP110444-P3, RP110444-P1)
  • National Institutes of Health
  • National Institute of General Medical Sciences (SC1GM084863)
  • National Institute on Minority Health and Health Disparities (G12MD007592)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
FKBP52, β-catenin, androgen receptor, prostate cancer, androgen receptor signaling, protein-protein interaction, ligand-binding domain, HSP90, transcriptional coactivation, androgen receptor antagonists
MeSH terms
Amino Acid Sequence, Binding Sites, HeLa Cells, Humans, Molecular Sequence Data, Protein Binding, Receptors, Androgen, Second Messenger Systems, Tacrolimus Binding Proteins, beta Catenin, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling. https://app.cochat.ai/papers/10.1371/journal.pone.0134015
The paper
Storer Samaniego, C., Suh, J. H., Chattopadhyay, A., Olivares, K., Guy, N., Sivils, J. C., Dey, P., Yumoto, F., Fletterick, R. J., Strom, A. M., Gustafsson, J.-Å., Webb, P., & Cox, M. B. (2015). The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling. PLOS One. https://doi.org/10.1371/journal.pone.0134015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.